KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for Amgen (AMGN) over the last 4 years, with Q3 2025 value amounting to $400.0 million.

  • Amgen's Asset Writedowns and Impairment rose 55573.77% to $400.0 million in Q3 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 65471.7%. This contributed to the annual value of $1.2 billion for FY2025, which is 65471.7% up from last year.
  • Amgen's Asset Writedowns and Impairment amounted to $400.0 million in Q3 2025, which was up 55573.77% from $800.0 million recorded in Q1 2025.
  • In the past 5 years, Amgen's Asset Writedowns and Impairment ranged from a high of $851.0 million in Q4 2023 and a low of $2.0 million during Q4 2022
  • In the last 4 years, Amgen's Asset Writedowns and Impairment had a median value of $64.5 million in 2024 and averaged $277.1 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first skyrocketed by 4245000.0% in 2023, then plummeted by 9647.47% in 2024.
  • Amgen's Asset Writedowns and Impairment (Quarter) stood at $2.0 million in 2022, then soared by 42450.0% to $851.0 million in 2023, then tumbled by 96.47% to $30.0 million in 2024, then soared by 1233.33% to $400.0 million in 2025.
  • Its last three reported values are $400.0 million in Q3 2025, $800.0 million for Q1 2025, and $30.0 million during Q4 2024.